Shingles

About Shingles Clinical Trials (Click to Open)

Join Clinical Trials for Shingles

Clinical Trials for ShinglesGeneral Purpose:

Singles (herpes zoster) is a blistering and painful skin rash that results from the re-activation of the dormant chicken-pox (varicella zoster) virus. This rash presents as an almost intolerable skin condition, and the while it is known that the chicken pox virus becomes active many years later, the cause of its re-activation is not known.

As a result, there are many clinical trials trying to delve deeper into Shingles for improved prevention and treatment methods. Observational studies conducted to expand our understanding of the underlying epidemiology of shingles are attempting to look at the role that age, immunity, and other related factors play on its developing.

By taking part in clinical trials for shingles, you will be among the first to obtain new treatments that may improve your health and prevent the development of shingles. You will also be helping improve the scientific body of data surrounding this widespread virus.

What will Clinical Trials for Shingles be like?

Clinical trials for shingles will conduct screenings of each potential participant, which may include medical history and clinical diagnosis of herpes zoster or varicella zoster virus.Clinical Trials for Shingles

Depending on the specific trial, the study doctor may request additional tests for each individual, such as blood samples. The goal is to ensure that you are the proper fit for a trial. Since the cause of virus re-activation remains unclear, there is an extensive range of prevention and interventional methods beings evaluated.

As a result, you must make sure to pick a clinical trial that you feel comfortable participating in after reading the informed consent and learning about what it will entail. Inclusion criteria are intended to provide benefit and avoid wasting your time.

Typical Shingles Clinical Trial Protocol:

Given the imprecise understanding of this virus, different trial protocols may vary greatly. Regarding prevention studies, methods may vary from exercise to strengthen immunity and resulting efficacy of the varicella zoster virus vaccine, to a more straightforward observational trial for an improved vaccination.

Most prevention studies will randomly assign you to a group. In this group you will participate in a treatment or a control for comparison. Studies of this nature will assess factors relating to varicella zoster virus immunity and attempt to demonstrate the prevention method results in significant changes in health and functioning.

Ultimately, the comparison between health improvements and varicella zoster immunity may be compared to determine a potential correlation. An interventional trial may conduct a comparative analysis between two different forms of antibiotics to determine which best treats shingles. They may also evaluate the benefit of an alternative treatment measure, such as a natural vitamin supplement.

Efficacy will be determined by follow up assessments of pain and other shingles’ symptom reduction. All clinical trials for shingles will help expand science’s working knowledge of this virus for the purposes of prevention and treatment, and the improvement of quality of life within the more susceptible geriatric population.

Suggested Search Terms:

Shingles Prevention, Varicella Zoster Vaccine, Activation of Chickenpox Virus, Shingles Treatment, Herpes Zoster

Current Search Term:

“Shingles”

Add Comments or Questions



Zoster Eye Disease Study


Condition:   Herpes Zoster Ophthalmicus
Interventions:   Drug: Masked Placebo;   Drug: Masked Oral Valacyclovir
Sponsors:   New York University School of Medicine;   National Eye Institute (NEI);   National Institutes of Health (NIH)
Not yet recruiting - verified April 2017


Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax vaccine
Sponsor:   HaEmek Medical Center, Israel
Recruiting - verified February 2017


Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified April 2017


Herpes Zoster Prevalence in Frailty Consultations


Condition:   Herpes Zoster
Intervention:   Other: Medical Questionary
Sponsor:   University Hospital, Toulouse
Completed - verified July 2016



Optimal Timing of Zoster Vaccine After Zoster Illness


Condition:   Shingles
Intervention:   Biological: Zostavax
Sponsor:   Seoul National University Hospital
Recruiting - verified October 2016


Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Recruiting - verified May 2017


Immune Response to Shingles Vaccination


Condition:   Shingles
Intervention:   Drug: Zoster Vaccine Live
Sponsors:   University of Washington;   Merck Sharp & Dohme Corp.
Recruiting - verified October 2016


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier


Condition:   Herpes Zoster
Intervention:   Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified January 2017


Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds


Conditions:   Shingles;   Herpes Zoster
Interventions:   Biological: Zostavax;   Biological: HZ/su vaccine;   Biological: Placebo
Sponsors:   University of Colorado, Denver;   GlaxoSmithKline
Active, not recruiting - verified February 2017


Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK 1437173A)
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Sponsor:   GlaxoSmithKline
Completed - verified January 2017


Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster vaccine (GSK1437173A)
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy


Condition:   Herpes Zoster
Interventions:   Biological: GSK 1437173A;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified July 2016


Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine (GSK 1437173A);   Drug: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older


Condition:   Herpes Zoster
Intervention:   Biological: Herpes zoster vaccine GSK1437173A
Sponsor:   GlaxoSmithKline
Completed - verified February 2017


Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified April 2017


ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)


Conditions:   Herpes Zoster;   Shingles
Intervention:   Biological: ZOSTAVAX™
Sponsors:   Merck Sharp & Dohme Corp.;   Kaiser Permanente
Active, not recruiting - verified April 2017


Herpes Zoster Vaccine for Bone Marrow Transplant Donors


Condition:   Herpes Zoster
Intervention:   Biological: Zostavax
Sponsor:   University of Sydney
Recruiting - verified May 2017


Study of Long Term Immune Responses and Safety of the GSK Herpes Zoster Vaccine in Healthy Subjects


Condition:   Herpes Zoster
Intervention:   Procedure: Blood sample
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents


Conditions:   Immunosenescence;   Shingles
Intervention:   Biological: Varicella Zoster Virus Vaccine (Zostavax)
Sponsors:   University of Colorado, Denver;   National Institute on Aging (NIA);   Merck Sharp & Dohme Corp.
Active, not recruiting - verified January 2017


Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older


Condition:   Herpes Zoster
Interventions:   Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults


Condition:   Herpes Zoster
Intervention:   Biological: Herpes Zoster Vaccine GSK 1437173A
Sponsor:   GlaxoSmithKline
Completed - verified May 2017


Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years


Condition:   Herpes Zoster
Interventions:   Biological: Herpes zoster vaccine GSK1437173A;   Biological: Placebo
Sponsor:   GlaxoSmithKline
Completed - verified March 2017


Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)


Condition:   Shingles
Interventions:   Biological: zoster vaccine live (Oka/Merck);   Biological: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified March 2017

Refine Your Search Advanced Search